Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia

Blood. 2009 May 14;113(20):5028-9. doi: 10.1182/blood-2008-11-191080.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Central Nervous System Neoplasms / prevention & control*
  • Central Nervous System Neoplasms / secondary*
  • Dasatinib
  • Genes, abl* / physiology
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Middle Aged
  • Pyrimidines / therapeutic use*
  • Recurrence
  • Thiazoles / therapeutic use*
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Pyrimidines
  • Thiazoles
  • Dasatinib